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  AN ABSTRACT OF THE THESIS OF  
RABINDRA KARKI, for the Master degree in Molecular Biology, 
Microbiology and Biochemistry, presented on 6/18/2014, at Southern Illinois 
University Carbondale. 
TITLE: REGULATION OF GLUCOSE METABOLISM BY Alox8 
MAJOR PROFESSOR: Dr. Daotai Nie 
Type II diabetes is one of the leading cause of morbidity in the U.S. and other parts of the 
world. Insulin resistance which precedes Type II diabetes is a complex state of the body where 
the body fails to respond to insulin. Its complexity lies in its multifactorial origin that is to say 
various environmental and polygenic components come into play. Here we try to dissect one of 
these components – ‘Alox8’ in transgenic mice and try to see if it affects blood glucose 
homeostasis. Comparison of glucose tolerance and insulin sensitivity among sixteen mice 
comprising of six wild type, five heterozygous and five knockout mice with respect to Alox8 
gene showed that wild type mice had relatively more glucose tolerance than knockout mice and 
this corresponded with relatively more insulin sensitiveness of wild type mice with respect to the 
knock out. However, these findings were not significant statistically at p=0.05. In search of any 
relevant biological significance, periodic acid schiff staining of the liver sections from these mice 
in three independent repeated experiments revealed that the knockout phenotype led to 
accumulation of glycogen deposits as compared to the wild type mice an indication of insulin 
resistance. 
Taken together, our data suggests that these findings when extrapolated to human which 
carries ALOX15B instead of mice orthologue Alox8, could lead to a benefit of administration of  
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lower doses of insulin in the wild type phenotype as compared to its polymorphic alleles carrying 
individuals. 
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                        CHAPTER 1 
                    INTRODUCTION 
1.1) Metabolism of Arachidonic acid  
“Eicosanoids” (Greek: eikosi – twenty) are metabolites of 20 C polyunsaturated fatty 
acids (PUFAs) generated primarily due to the action of three distinct enzymes : Lipoxygenases 
(LOXs), Cyclooxygenases (COXs) and Cytochrome P450 (CYP)  which we collectively propose 
to be called as “ Eicoxygenases”  on arachidonic acid (AA) (1).  The biosynthesis of eicosanoids 
in mammalian cells generally begin due to the activation of phospholipase A2 (cPLA2α) which 
releases the substrate AA from sn-2 position of glycerophospholipids (2, 3) of the cell membrane 
(1, 4, 5) in response to various stimuli (6) that usually occur under inflammatory conditions (5) 
such as growth factors , cytokines (5,7) oxidative stress, complement C5b-9, hypoxia, 
mechanical stretch, endothelin, angiotensin II,  vasopressin (7) and wound (8) ( figure 1). 
LOX enzymes occur in various forms of life including bacteria (9, 10), fungi, plants and 
animals (11) but not in archaea (12).  LOX (EC. 1.13.11.12) consists of single polypeptide chain 
of MW ~ 75-80 kDa (12) folded into two domains: a noncatalytic N-terminal β- barrel domain 
and a catalytic C-terminal domain (10, 12). The non-heme iron is held in the catalytic domain of 
the enzyme by interaction with conserved histidines ( H361, H366, H541, H545) and a 
conserved carboxylic group of isoleucine moiety at the C- terminal end (11,12). Oxidation of the 
iron to ferric state is required for catalysis (12), figure 2. 
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Fig.1 Fate of AA due to the action of “ eicoxygenases” .   
 
 
                                                     
Fig. 2 A 3D structure of 15-LOX showing N-terminal β- barrel domain and a C-terminal 
catalytic domain and a non heme iron shown as a purple  ball (Adapted from Kuhn et al., 2002).  
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Seven genes encode LOXs in mouse whereas six homologues and an expressed 
pseudogene (ALOX12P2) exist in humans (5, 12, 14) figure 3. 
 
Fig.  3 Comparison of lipoxygenase gene family between two species viz. Mouse and Human. 
            These non-heme iron containing enzymes carry out the insertion of hydroperoxy group 
(13) into  cis double bonds (12) or 1Z, 4Z- pentadiene moieties of polyunsaturated fatty acids 
(10) like AA (7, 15) and linoleic acid (14) with varying stereoconfiguration (S or R) (16). 
According to the position of insertion in AA, these are classified as 5-LO, 8-LO, 12 LO and 15-
LO (15, 16, 17). The initial reaction of LOXs with AA, results in corresponding 
hydroperoxyeicosatetraenoic acid (5-, 8-, 12- or 15- HPETE)  whereas with linoleic acid (LA) 9- 
or 13-hydroperoxyoctadecadienoic acid are produced which undergoes further reduction by 
glutathione peroxidase to yield hydroxyeicosatetraenoic acid (5-, 8-, 12- or 15- HETE) (1) and 
hydroxyoctadecadienoic acid (9-or 13-HODE) respectively (9, 19) .   
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Fig. 4 Metabolism of AA via Lipoxygenase pathway.  
            LOX generated products act in an autocrine or paracrine fashion via interaction with G 
protein coupled cell surface receptors and nuclear receptor – peroxisome proliferator activated 
receptors (PPARs) (18). Activation of LOXs have been noted in numerous health conditions like 
atherosclerosis (14), diabetes (19, 20) and vascular remodelling (14). Based upon 
carcinogenicity, LOXs are classified as procarcinogenic which includes 5-, 8-, and 12- LO or 
anticarcinogenic (15-LO-2) (16). Hydroxyeicosatetraenoic acids (HETEs) and leukotrienes (LTs) 
are the two major metabolites derived from LOX action upon AA (3, 15) . HETEs can activate 
protein kinase C (PKC) and mitogen activated protein kinases (MAPK) and thereby activating 
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key transcription factors that promotes expression of genes involved in growth and inflammation 
(7). 
            The 5-LO which with the help of 5-LO activating protein (FLAP) interacts with AA 
(4,12,15) and metabolizes the latter into 5- (S)-HPETE ( 5-hydroperoxyeicosatetraenoic acid) 
which under further metabolism yields 5(S)-HETE ( 5(S)-hydroxy-6,8,11,14- eicosatetraenoic 
acid) (7) and LTA4, a precursor of downstream LTs (4). LTA4 under hydrolysis yields LTB4. 
LTA4 further can conjugate with glutathione to form cysteinyl-LTs (cysLTs), LTC4, LTD4 and 
LTE4 (1,15, 21). As the name suggests, leukotrienes are the major products in white blood cells 
like eosinophils, monocytes/ macrophages, neutrophils and mast cells and they exert 
proinflammatory effects by inducing production of proinflammatory cytokines and also 
recruiting inflammatory cells in nearby tissues (1,15). 
            12-LO oxygenates polyunsaturated nonesterified fatty acid to produce 12-HPETE and 12-
HETE (22). Three different types of 12- LO exists viz. leukocyte, platelet and epidermal (12, 15) 
which differ in sequence, catalytic activities and function (12). 12-LO is often designated by its 
stereoconfiguration as in 12R-LOX or 12S-LOX (12).  12(S) - HETE is a major LOX product in 
the pancreatic islet where it induces β-cell death (15).  12-LO products promote atherogenesis by 
enhancing the interaction of monocytes with vascular endothelium and participates in oxidative 
modification of lipoproteins and membrane lipids (24). 
            15-LO-1 (reticulocyte/ leukocyte 15-LO-1) metabolises AA into 15(S) HETE and lipoxin 
(LX) and occurs in polymorphonuclear leukocytes (PMNs), reticulocyte, eosinophils and airway 
epithelial cells (18). With LA, the product is 13-HPODE (13- hydroperoxyoctadecadienoic acid) 
and 13-(S)-HODE (hydroxyoctadecadienoic acid) (19, 20). One remarkable feature of 15-LO-1 
is that it can convert LTA4 into LXs (1).  LXs are believed to be involved in wound healing and 
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resolution of inflammation unlike other eicosanoids which provoke the inflammatory process (1). 
Mammalian 15-LO-1 is known to play a significant role in the maturation of red cell by causing 
peroxidation of membrane lipids and thereby inducing structural changes. Besides it is also 
known to initiate atherosclerosis by oxidation of low density lipoprotein (LDL) (12). 15-LO-1 
preferentially, does the conversion of linoleic acid to 13(S)-HODE and is known to have 
procarcinogenic role (16). 
 15-LO-2 (epidermis type) unlike 15-LO-1 converts AA exclusively to 15(S)-HpETE and 
15(S)-HETE and occurs in prostate, skin and lung (23), cornea but absent in pheripheral blood 
leukocytes (11). 15-LO-2 shows only a partial sequence homology to 15-LO-1 and is remarkably 
distinct from the latter when it comes to chemical and enzymatic properties. Its role is speculated 
in relation to skin functionality and prostate cancer (11). 
            Human and rabbit reticulocyte 15-LO-1 as well as the murine/ rabbit leukocyte- type 12-
LO have high homology and share a common enzymatic activity and hence are classified under 
12/15 LO especially in rat and mouse (11, 17, 18). There exists no separate gene for leukocyte-
type 12-LOX in humans. However separate genes encoding for both reticulocyte type 15-LO-1 
and leukocyte type 12-LO exist in case of rabbit.  Gene sequencing studies show that these 
isoforms share >99 % identity implying they might be the result of gene duplication (11). 12/15 
LO unlike other LOXs can insert molecular oxygen at 12th and/or 15th position in AA (20:4) 
thereby producing corresponding hydroperoxide. Whereas with LA (18:2) the insertion occurs at 
9th and/or 13th positions (24).  In humans and rabbit  12/15 LO activity results in 15-HPETE as 
the dominant product hence the enzyme is preferably called as 15- LOX  whereas, in case of rat, 
mouse, pig and cow,  12-LO  activity is the dominant one (12, 14). The substrates for 12/15 LO 
may be either free unsaturated fatty acids or fatty acids in phospholipids and cholesteryl esters 
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(18, 26). Peroxidation of polyunsaturated fatty acids present in the biomembrane causes 
alteration in the membrane structure contributing to cellular remodeling (14). 12/15 LO occur in 
dendritic cells, differentiated macrophages, inflamed endothelial and smooth muscle cells and in 
some tumors (26). 12/15 LO in mammals regulate MAPK, PKC, small GTPases like Ras and 
Rho A and NF-kB (26). 12/15-LO can mediate oxidation of LDL promoting atherosclerosis 
(7,8).   
            In mouse, AA when metabolized by 8(S)- lipoxygenase (8-LO) leads to the formation of 
8-hydroperoxy-5,9,11,14- eicosatetraenoic acid (8-(S)-HPETE) which is further reduced to 8(S)-
HETE. Based on sequence identity, structure and chromosomal location, human epidermis type 
15(S)-LO-2 which is located in chromosome 17p13.1 is considered as the orthologue of mouse 
8-LO located in chromosome 11, central region although they insert dioxygen at different 
positions .  However, the gene encoding 8-LO is designated as Alox 15b commemorating 15-LO-
2 encoding ALOX 15B of humans. 8(S)-HETE in rats and mice has been detected in corneal 
epithelium and skin like its human orthologue 15-LO-2  . 8(S)-HETE plays a role in terminal 
differentiation of keratinocytes (25). 
            Prostanoids are  arachidonic acid derived metabolites due to the acting upon by the 
enzyme –cyclooxygenase (COX/PTGs) which by itself exists in two isoforms viz. COX-1 and 
COX-2 (8,25,28,29,30) . COX-1 is encoded by cox-1 gene whereas cox-3 splice variant and cox-
2 encode COX-2 (30).  Besides being regulated post-transcriptionally, STAT-1, STAT-3, NF-kB, 
NF-IL6 induce COX-2 via cis-acting elements whereas other stimuli upregulate cox-2  via 
cAMP- response element (CRE), peroxisome-proliferator-activated receptor-responsive element 
and CCAAT enhancer (26). The two isoforms have comparable activity albeit expressed 
differentially with cox-1  being constitutive in most tissues and cox-2  being inducible 
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(1,7,8,15,25,28,29,31,32). However, recent findings show that cox-2  is constitutive in kidneys 
(2,22,25), brain, tracheal epithelium, some endothelial cells (25) and pancreatic islets 
(7,15,31,33,34).  COX-1 performs housekeeping functions as in cytoprotection of the gastric 
mucosa, regulation of platelet aggregation (8) and renal water balance (25). However, COX-2 is 
involved in pathophysiological processes like angiogenesis, inflammation and tumorigenesis and 
is induced by mitogens, inflammatory mediators (8) hyperglycemia (27, 29) lipopolysaccharides 
and chemicals (34). AA gets converted first to prostaglandin (PG)G2 via bis-oxygenase activity 
of the enzyme which is then subsequently converted to endoperoxides (PGH2) due to peroxidase 
COX- activity (8) which upon further acting by specific synthases yields respective prostanoids/ 
prostaglandins like : prostacyclin (PGI2), thromboxane A2 , prostaglandin D2 (PGD2), 
prostaglandin E2 (PGE2) and prostaglandin F2α (PGF2α) (28, 32).  Five G-protein coupled seven 
transmembrane receptors are engaged in interacting with prostanoids. These are: DP, EP, FP, IP, 
and TP which interact with prostaglandins D2, E2, F2α, I2 (prostacyclin) and thromboxane A2 
respectively (4).  Some prostanoids however may engage with nuclear receptors such as PPAR δ 
and PPAR γ. There are four subtypes of EP receptors viz. EP1, EP2, EP3, and EP4. The G-protein 
coupled signaling cascade initiated by each prostanoids is distinct. For instance, EP3 receptor 
interaction to an inhibitory G protein reduces cyclic adenosine monophosphate (cAMP) 
synthesis. Whereas IP, DP, EP2 and EP4 receptors coupled to stimulatory G protein results in 
signaling cascades due to increasing cAMP  rather than inducing calcium mobilization as with 
TP, FP, and EP1 receptors.  Depending upon the type of prostanoids and receptor interactions, 
the role played by prostanoids is diverse (8).  The biosynthetic pathways for prostanoids is 
shown in figure 5 below (28). 
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 Fig.5 Biosynthetic pathways for prostanoid from arachidonic acid.   
            CYP monooxygenases, first described in 1980 consists of two enzymatic pathways-the 
epoxygenases and the hydroxylases (2,34). Epoxyeicosatrienoic acids (EETs) are metabolites of 
AA  due to the action of epoxygenases and are endothelial in origin and plays diverse spectrum 
of roles from activating Ca
2+
 -sensitive K
+
 channels thereby inducing hyperpolarization  (29, 30, 
31) based vascular dilatation of coronary, renal and cerebral arteries to anti-inflammatory effects 
in such tissues (32) and  proliferation of endothelial, epithelial and smooth muscle cells (33, 38). 
The four cis- regioisomers of EETs (based on location of double bond across which epoxide is 
added)  that are produced from AA by the action of cytochrome P450 (P450 or CYP) 
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epoxygenases of 2C and 2J classes (34) in the presence of NADPH and oxygen (52) are : 5,6-
EET, 8,9-EET, 11,12-EET, and 14, 15-EET (6,36,38,41) which gets metabolized via β-oxidation 
into shorter chain fatty acids and  vicinal-dihydroxyeicosatrienoic acids ( DHETs) by soluble 
epoxide hydrolase (sEH ) in mammalian system (38, 43). Each EET regioisomer exists in two 
enantiomeric forms based on how epoxide group is attached to the double bond viz. R/S and S/R 
thus giving rise to eight different EETs each with different biological effects (42). Whereas the 
epoxygenases results in EETs from AA metabolism, ω- hydroxylases belonging to the classes 
CYP4A and CYP4F (22) in extrahepatic tissues also lead to the formation of 7-, 10-, 12-, 13-, 
15-, 16-, 17-, 18- HETEs and 19- and 20- hydroxyeicosatetraenoic acids (19- and 20-HETE) 
(2,36,42). Because of various cardiovascular protective effects of EETs, the therapy for treating 
such cardiovascular diseases is centered on targeting sEH and thereby stabilizing EETs (36). The 
summary of CYP based metabolism of AA is depicted in figure 6. 
 
Fig. 6 Metabolism of AA via CYP pathway.  
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1.2) Diabetes 
            According to International Diabetes Federation, the global prevalence of diabetes was 
382 million in the year 2013.  Hyperglycemia due to insulin secretory defect or failure of insulin 
action or both results in diabetes mellitus   and under chronic conditions leads to damage or 
dysfunction  of eyes, kidneys, blood vessels, heart, nerves (35, 36).  Various risk factors of 
diabetes are: sedentary life style, hypertension, dyslipidemia, family history of diabetes, history 
of gestational diabetes and polycystic ovary syndrome (37). Diabetes often leads to poor 
prognosis of cardiovascular diseases like atherosclerosis and hypertension (7, 38, 39, 40, 41) and 
renal diseases (42).  > 700, 000 annual deaths in the U.S. are attributed to diabetes induced 
cardiovascular diseases and further it has been estimated that the subclinical states of glucose 
intolerance will increase (50) 40% death risk due to cardiovascular complications in adults as 
compared to 110% risk among overt diabetics  independent of other risk factors for 
cardiovascular diseases (49).  It has been estimated that the global burden of diabetes would be 
increased to 439 million adults by 2030 and this would be mainly due to increase in cases among 
developing countries rather than in developed countries.  The reason being obvious decrease in 
physical activity but increase in obesity (43). Impaired glucose tolerance (IGT) is common ( 1.5 
times Type II diabetes) in the U.S. accounting 11.2% adults of age 20 to 74 years (44).  IGT but 
not impaired fasting glucose (IFG) has been identified to be an independent risk factor for 
cardiovascular diseases (45). However, IFG and IGT are used to predict risk of developing 
diabetes (46, 105) as they occur as an intermediate stages in the natural history of diabetes 
mellitus (47). Hyperglycemia induces mitochondria to overproduce reactive oxygen species 
(ROS) which leads to induction of tissue damages through following five pathways: 1) increased 
formation of intracellular AGEs (advanced glycation end products) 2) increased expression of 
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the receptor for AGEs and its activating ligands 3) activation of protein kinase (PK) C isoforms 
4) increased flux of glucose and other sugars through the polyol pathway  and 5) hexosamine 
pathway overactivity (31, 46). 
1.2.1) Type I diabetes 
            Type I diabetes also known as insulin dependent diabetes mellitus (IDDM) or juvenile 
onset diabetes accounts for 5-10% of all diabetics results from immune attack to the pancreatic 
beta cells (45, 48). Increase in autoantibodies to insulin, glutamic acid decarboxylase (GAD65 ) , 
tyrosine phosphatases IA-2 and IA-2β (45),  carboxypeptidase-H, islet cell antigen (ICA)-69, 
GM gangliosides and SOX13 (59)  are markers of beta cells destruction . Both genetic and 
environmental factors come into play in the onset of Type I diabetes (59, 105).  
            The onset of Type I diabetes is characterized by infiltration of inflammatory cells (29,49, 
50) particularly CD4
+
 and CD8
+
 T cells, monocytes and macrophages (31, 58, 59) which release 
various cytokines like IL-1 β that induce expression of COX-2 that result in production (35) of 
proinflammatory mediators like  prostaglandins and thromboxanes  and iNOS (inducible nitric 
oxide synthase) that produce NO radical.  It is due to these metabolites that leads to destruction 
(34,62) and apoptosis of pancreatic islets (51) . 70-80 % of β cell mass is lost in type I diabetes 
(52). Affected individuals depend upon exogenous source of insulin for life and are at high risk 
of developing serious cardiovascular and microvascular complications (60). 
1.2.2) Type II diabetes 
            Around 285 million adults globally suffer from type II diabetes (105) also known as adult 
onset diabetes (45).  This form of diabetes which is most prevalent account approximately 90-
95% of total diabetics (45). Type II diabetes or non-insulin dependent diabetes mellitus is a result 
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of insulin resistance and β- cell dysfunction (35,53, 54, 105). The latter process encompasses 
phenomena like: loss of glucose sensing and thereby decrease in glucose stimulated insulin 
secretion (GSIS), increased basal insulin secretion, decrease in insulin content of the islet, altered 
gene transcription, changes in intracellular signaling intermediates (65) and loss of β- cell mass 
(35, 65). It has been observed that there is 25- 50 % loss of β- cell mass in Type II diabetes (15) 
but this is not due to autoimmune destruction (45). Initially, there is hyperinsulinemia to 
maintain normoglycemia  but later on due to progressive insulin resistance and β- cell destruction 
leads to hyperglycemic state (15). Chronic exposure to elevated levels of glucose and free fatty 
acid (FFA) induce β- cell apoptosis particularly via ER-stress which is independent of  IL-1β, 
NF-kB or NO  and is unique from β- cell death during type I diabetes (64).  However, some 
study has shown that elevated level of glucose also has been shown to induce IL-1β production 
by the beta cells and there by leading to their own apoptosis (29) this contrast with other findings 
where no induction of IL-1β due to high glucose was noticed (64).  
            Release of insulin under glucose stimulation by the pancreatic beta cells is a biphasic 
process. The first phase that lasts 10-15 minutes is extremely dependent upon elevated level of 
intracellular [Ca
+2
]i level. Whereas the amplifying signals resulting from glucose metabolism 
initiates the second phase and is less oscillatory [Ca
+2
]i dependent. Partial or complete defect in 
the first phase of insulin secretion marks the onset of type II diabetes whereas defect in second 
phase occurs secondary but is prominent too (66). Although type II diabetic patients, have 
normal level or elevated level of insulin at the baseline, they cannot respond to higher glucose 
level due to defect in insulin secretion (45).  
            Type II diabetes is a major risk factor for health complications like hypertension, 
cardiovascular diseases, dyslipidemia, infections, renal failure, blindness and amputations due to 
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microvascular complications (45, 105). Obesity is often associated with type II diabetes (15, 55). 
However, a distinct link of genetic trait to this form of diabetes has not been delineated (45). 
1.3) Mode of Insulin action 
Insulin acts by binding to the growth factor receptor tyrosine kinases subfamily of cell 
surface receptor which includes insulin receptor (Insr), type I insulin-like growth factor (IGF) 
receptor (Igf1r) and Insr-related receptor (Irr). Although being an structural analogue, the roles 
played by these receptors vary although intracellular signaling cascades coincide, with Insr 
being involved in fuel metabolism and Igf1r in growth. Insulin, Igf1 and Igf2 activate the former 
two receptors but not the third one making it an orphan receptor (56).  The glucose homeostasis 
maintenance due to insulin is a result of its pivotal role intertwined among metabolism of three 
major nutrients: carbohydrate, protein and fats by acting upon liver, muscle and fat cells. Insulin 
stimulates liver cells to uptake glucose and store as glycogen but at the same time preventing 
gluconeogenesis and glycogenolysis. Whereas in case of muscle and fat cells, it stimulates 
uptake, storage and use of glucose. 
            Upon binding of insulin to its receptor, the tyrosine residue of the intracellular region of 
the receptor gets phosphorylated thus activating receptor tyrosine kinase activity. This activity 
leads to phosphorylation of protein tyrosine which inturn initiates a signaling cascade. Of interest 
is the phosphorylation of serine kinase at the serine residue. This activates the latter which 
phosphorylates protein phosphatase 1 at the serine residue and activates it. The activated, protein 
phosphatase1 has dual functions: first, it dephosphorylates the glycogen synthase~Pi to glycogen 
synthase which causes increase in glycogen synthesis and second, there occurs 
dephosphorylation of phosphorylase kinase~Pi to phosphorylase kinase which leads to inhibition 
of glycogenolysis. This occurs usually in the liver and muscle cells where as in case of fat cells, 
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lipogenesis is encouraged, this tissue specific discrepancy is due to the fact that there occurs 
disparity of enzymes involved in the lipogenesis among these tissues with much abundance of 
these enzymes occurring in the fat cells (57) (figure 7).  
            The binding of the insulin to its receptor also initiates other signalling pathways that are 
of interest. For instance, the activated tyrosine receptor activity leads to the phosphorylation of 
Src and Insulin receptor substrate (IRS) which inturn activate GRB2.  GRB2 and SOS, two 
exchange factors then form a complex which inturn activate Ras          Mitogen activated protein 
(MAP) kinase pathway thereby stimulating growth and proliferation of cells.  The IRS          
phosphatidylinositol-3-kinase (PI3K) pathway leads to activation of downstream kinases like 
pdk1 which in turn phosphorylates and activates serine/ threonine kinases like isoforms of Akt. 
Akt inturn phosphorylates, glycogen synthase kinase 3 (Gsk3), cGMP-inhibitable 
phosphodiesterase b and Foxo transcription factors which leads to stimulation of glycogen 
synthesis, inhibition of lipolysis and gene expression. PI3K has been stated as necessary but not 
sufficient cause for glucose transporter translocation. A new PI3K independent pathway for 
insulin dependent uptake of glucose is based on activation of protooncogene c-Cbl. It is believed 
that this or related pathway aids in glucose transporter recycling by remodeling cortical actin 
filaments with possible involvement of atypical myosin isoforms (68). 
1.4) Lipoxygenases and diabetes 
            12/15-LO has been shown to induce production of proinflammatroy cytokines and cause 
reduction in beta cell mass thereby causing type I diabetes in mice (60).  12-LO in mice makes 
pancreatic islets more sensitive to cytokines and enhance nitric oxide synthesis in peritoneal 
macrophage and thereby induce type I diabetes (58). 12-LO products have been implicated in the 
pathogenesis of both type I and type II diabetes. It has been demonstrated that 12-(S)- HETE 
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induce apoptosis in beta cells (15,17). However, no literature exists regarding the role of Alox8 
in glucose metabolism or diabetes.  Further, the goal of the study was also supported by the fact 
that PPARα which is an endogenous ligand for 8(S)-HETE gets down regulated in zucker 
diabetic rats implying that 8-LO might play anti-diabetic role (8) . Hence to understand the role 
played if any by 8-LO in glucose homeostasis in mice, this study was conducted.  The study 
revealed a biologically significant role of this enzyme in maintaining lower blood glucose level 
in mice. 
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                  CHAPTER 2 
               MATERIALS AND METHODS 
2.1) Animals 
            Wild type (WT) mice C57BL6 and Alox8 
-
/
-
 knockout (KO) mice were obtained from the 
Jackson Laboratories.  These mice were used for breeding and the heterozygous off springs were 
interbred further to generate the KO mice required for the experiment. The mice were housed at 
room temperature under controlled light comprising 12: 12  (light : dark ) cycle under pathogen 
free conditions with free access to normal feed ( Purina Lab Diet 5001, Gateway Lab Supply) 
and water all the time. Mice were housed usually 1-3 per cage but not more than 5.  All 
procedures including were carried out with total compliance to the guidelines of the National 
Institutes of Health and as per the protocols that were reviewed and approved by the committee 
on the Use and Care of Laboratory Animals (LACUC) of Southern Illinois University School of 
Medicine Springfield, Illinois. 
2.2) Genotyping 
            Weaning and genotyping of the mice were carried out at the age of 21 days. Tail tissue was 
used to obtain DNA. Briefly, mice were anesthetized and tail tip less than 5 mm were sterilized 
and snipped off using a pair of sterilized scissors. The downstream extraction was done 
according to the protocols of available commercial kits (ArchivePure DNA Cell/Tissue and 
Tissue Kits, 5 PRIME). For genotyping following primers were used: Alox8wtF - 5’CCC AGA  
AAT ACA AAG  GTT  TAG  ATT TT-3’ ;  Alox8wtR- 5’AGA CAA ATT GGT ACG GGG 
AAT GG-3’ and  Common-LoxP-F— 5’ GAG  ATG  GCG CAA CGC AAT TAAT-3’ ;  CSD-
Alox8-R— 5’ AAG GCT CCT ACA GGT CTC TTT TGA CC-3’ . The PCR product size for WT 
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was 700 bp whereas  for KO it was 350 bp  using the above sets of primers. The PCR cycling 
conditions used were as follows: Initial denaturation  at 92 ºC for 2 minutes followed by 34 
cycles of  denaturation at 92 ºC for 30 seconds , annealing at 56 ºC for 30 seconds and extension 
at 72 ºC for 40 seconds followed by a final elongation at 72 ºC for 5 minutes.  GoTaq® qPCR 
Master Mix  ( Promega) was used for the process. 
2.3) Intraperitoneal Glucose tolerance test (IPGTT) 
            Age matched male mice (59) were fasted for 16 hours prior to the conduction of the test.  
The mice had however access to the water. On the test day, the weights of the mice were taken. 
Tip of the mouse tail was surfaced sterilised by wiping with 70% ethanol and then with a sterile 
razor blade, the tail was incisioned just enough to collect 5- 10 ul of blood from the tail vein . 
Baseline blood glucose was noted. Then the mice were injected peritoneally with glucose 
solution made in sterile 0.9 % normal saline. Whereas the control mice received only 0.9 % 
normal saline. The amount of glucose injected was at the rate of 2mg/ gram body weight or 1mg/ 
gram body weight depending upon the experimental purpose. However, no more than 200 μl of 
solution in toto was injected. After injection, the same tail wound was scrapped for further blood 
glucose testing every 5 min, 15 min, 30 min, 60 min and 120 min respectively. All the readings 
were noted. ReliOn® Prime glucose meter was used for the process.  
 
2.4) Intraperitoneal Insulin tolerance test (IPITT) 
            Age matched male mice (71) were fasted for 5 hours prior to the conduction of the test.  
The mice had however access to the water. On the test day, the weights of the mice were taken. 
Tip of the mouse tail was surfaced sterilised by wiping with 70% ethanol and then with a sterile 
razor blade, the tail was incisioned just enough to collect 5- 10 μl of blood from the tail vein . 
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Baseline blood glucose was noted. Then the mice were injected peritoneally with porcine insulin 
(Sigma-Aldrich ) solution made in sterile 0.9 % normal saline. Whereas the control mice 
received only 0.9 % normal saline. The amount of insulin injected was at the rate of 0.5 U/ Kg 
body weight . However, no more than 200 μl of solution in toto was injected. After injection, the 
same tail wound was scrapped for further blood glucose testing every 5 min, 15 min, 30 min, 60 
min and 120 min respectively. All the readings were noted. ReliOn® Prime glucose meter was 
used for the process. 
 
2.5) Histopathology 
            Mice from the three genotypes were euthanized and then sacrificed by cervical 
dislocation. Then immediately liver tissue was isolated and then fixed in 10 % formalin and then 
embedded in paraffin. The embedded blocks were sectioned at the thickness of 4 μm for staining 
via H & E (HE), periodic acid-schiff (PAS) and PAS- diastase (PASD) methods. And the 
readings were taken at the same exposure of light. 
 
2.6) Statistical Analysis 
            Mean body weights and ages of the mice were compared among the genotypes by using 
unpaired Student’s t-test. Area under curves (AUCs)   were compared by using One- way 
analysis of variance (ANOVA).  Values were expressed as mean ± SEM.  P value of   ≤ 0.05 was 
considered to be significant. 
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    CHAPTER 3 
      RESULTS 
3.1) Genotyping 
            All the mice were genotyped as per the protocol mentioned in the materials and methods 
section at the inception of the experiment. A representative genotyping profile of the three 
different genotypes is shown in figure 8. 
 
3.2) Alox8 -/- mice has lower glucose tolerance 
            Sixteen mice with the following distributions: WT = 6; Het = 5 and KO = 5 were taken 
for the IPGTT.  The age and weight distribution of the mice are shown in table 1.  One-way 
ANOVA for the age distribution of the mice among the three different genotypes showed no 
significant difference, p = 0.87. However, the weight distribution showed a significant 
difference, One-way ANOVA p= 0.017 with the KO mice being slightly heavier than the WT. 
The blood glucose levels at various time points of the IPGTT for these mice is shown in table 2. 
The same thing is depicted in the form of line curve to see the dynamics of blood glucose levels 
with time in the three genotypes (figure 9). 
            Mean area under curve (AUC) values obtained from the glucose tolerance is shown in   
table 3.  One-way ANOVA analysis of AUCs showed insignificance in blood glucose 
distribution among the three genotypes with p value of 0.124.  However, there was a slightly 
higher glucose level trend among the KOs as compared to the WT mice (figure 10). 
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3.3) Alox8 
+/+
 mice are comparatively more responsive to insulin than the KO 
            Sixteen mice with the following distributions: WT = 6; Het = 5 and KO = 5 were taken 
for the IPITT.  The age and weight distribution of the mice are shown in table 4.  One-way 
ANOVA for the age distribution of the mice among the three different genotypes showed no 
significant difference, p = 0.88. However, the weight distribution showed a significant 
difference, One-way ANOVA p= 0.058 with the KO mice being slightly heavier than the WT. 
            The blood glucose levels at various time points of the IPITT for these mice is shown in 
table 5. The same thing is depicted in the form of line curve to see the dynamics of blood glucose 
levels   with time in the three genotypes ( figure 11). 
            Mean drop in blood glucose level five minutes after IPITT in three genotypes is shown in  
table 6. One-way ANOVA analysis of these mean drop in blood glucose level among three 
genotypes at five minutes time point after insulin administration showed insignificance with p 
value of 0.717. However, a rapid drop in blood glucose level among the WT mice as compared 
to the KOs was observed although statistically invalid (figure 12). 
 
3.4) Histology 
            The pictures of the liver sections obtained from the three different genotypes of mice are 
shown as figures 13 and 14.  The sections were stained by HE, PAS and PASD. HE staining of 
the liver sections showed no significant changes in the cell or nuclear morphology (figure 13).  
However, a trend in PAS stain intensity was observed among three genotypes in all three 
repeated batch of independent experiments (figure 14). 
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     CHAPTER 4 
              DISCUSSION 
            Diabetes is a costly (partly because it is chronic) disease that claims huge economic loss 
to a nation (15, 60, 105) . In its subclinical stages, the disease is manifested in the form of 
impaired glucose tolerance or impaired fasting glucose (45, 47). All these together have been 
proved to be an independent risk factors for various cardiovascular (7, 48, 52, 70) and 
microvascular complications leading to severe health consequences like neuropathy  , 
retinopathy (45), renal complications (52), amputations and so on (46) .  Various genetic (eg. 
PPARγ, ABCC8, KCNJ11, CALPN10 for type II diabetes) (61) and environmental factors have 
been linked to the predisposition of this malady (64). The important environmental factors that 
are linked strongly to diabetes are obesity and physical inactivity (54). Due to unhealthy diets , 
obesity, population growth and advancement in technologies, that causes  reduction in physical 
activity in our daily lives, a increase in prevalence in diabetes in the upcoming years particularly 
in the developing nations has been predicted (54, 72).  
            Lipoxygenases particularly 12-LO (24, 70) and 12/15- LO (7, 60) have been correlated to 
cause type I diabetes. And this has led us to the belief that 15-LOX 2 might possibly play some 
role in glucose homeostasis. Here in this study, we tried to study the role of  Alox8 gene, which 
is a mouse orthologous for human 15-LO2, in glucose metabolism if there exists any. 
           Our hypothesis was also supported by the fact that our  KO mice had significantly higher 
baseline blood glucose level than the WT ( p = 0.0072) (  Supplementary table 7). We began the 
study by looking for tolerance for glucose among the three genotypes. As shown in fig. 9, the 
trend in glucose metabolism over time were similar for both the WT and KO mice.  Also, the 
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AUC for blood glucose level for KO was higher as compared to the WT although not statistically 
valid (p =0.124) (figure 10). 
            We further tried to figure out if this poor tolerance of glucose in KO mice was due to 
resistance to insulin in this cohort of mice.  For this we carried out insulin tolerance test, the 
trend in level of blood glucose after insulin administration is shown in figure 11.  There are 
controls ( 0.9 %  PBS) which shows increase in blood glucose level after injection in mice , this 
is due to the fact that trauma due to injections cause release of hormones like cortisol which 
leads to elevated blood glucose level .  Since the half-life of insulin is ~ 10 minutes in mice, we 
tried to see if there is some effect of insulin within the first 15 minutes after its administration 
(71).  Since the trend lines among the two genotypes showed some remarkable difference at 5 
minutes and 15 minutes time points (fig. 11), we performed statistical analysis to see if the 
difference was significantly valid. However, difference in drop of blood glucose levels at both 
the time points of 5 minutes and 15 minutes revealed insignificance in the nature of data with 
corresponding one way ANOVA p values of 0.717 and 0.528 respectively. However, in 
conformity to the glucose tolerance test trend line, there was a slightly higher drop in blood 
glucose level among the WT mice as compared to that of the KO mice 5 minutes after insulin 
administration (figure 12). This data tells us that insulin may have biological significance in 
lowering blood glucose level among the WTs although not valid statistically. 
            Next we tried to question why was this effect of insulin acting so differently among the 
two, otherwise seemingly comparable, genotypes?  The reason for this insulin resistance (IR) 
may be various. One clear reason for IR is obesity (26, 62, 63, 64).  There occurs macrophage 
infiltration and inflammation (26,76) in the adipose tissue, this leads to inactivation of IRS by 
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cytokine-activated JNK, IKKβ and SOCS ultimately causing resistance to insulin action. 12/15-
LO has also been shown to cause infiltration of macrophages to adipose tissue and thereby 
causing release of proinflammatory cytokines ultimately leading to whole body insulin resistance 
(26). Besides storage of excess calories in the form of fat , adipose tissue is a metabolically 
active site for synthesis and release of bioactive compounds like proinflammatory cytokines 
(TNF-α, IL- 1β, IL6, MCP1) , leptin, resistin, adiponectin, PAI-1, acute phase reactants, 
angiotensin II and so on . And it has been known that some of these compounds in high dose 
leads to the development of IR ( 65, 66, 67). FFA which increases with obesity is known to 
induce IR and drugs like thiazolidinediones (TZDs) are based on increasing insulin sensitivity by 
causing oxidation of FFA and thereby lowering their content. One mechanism of IR due to high 
FFA is believed to be due to intramyocellular and intrahepatic accumulation of triglycerides and 
metabolites of FFA reesterification pathway such as long chain Acyl-CoAs and diacylglycerol 
(DAG). And it has been shown that DAG leads to activation of protein kinase C (a serine 
threonine kinase) isoforms which cause decrease in tyrosine phosphorylation of the IRS thereby 
inhibiting the insulin signaling pathway. Also it has been known that FFA in adipocytes leads to 
oxidative stress by generating reactive oxygen species which causes deregulated generation of 
proinflammatory cytokines which participates in IR.  Further, FFA in adipocytes, liver cells and 
pancreatic beta cells is known to cause ER stress which then activates JNK that leads to IR (78). 
Leptin, a fat derived hormone reduces intracellular fat accumulation. Hyperleptinemia, occurs 
early in obesity due to resistance of extra adipose tissues to leptin and thereby leading to lipid 
accumulation and lipotoxicity which promotes IR (68). Low –grade chronic inflammation is 
associated with IR and type II diabetes, and IL-6 which is produced during such inflammation 
has been known to interfere with the Insuin receptor downstream signaling leading to IR in liver 
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and adipose tissues (69). Study has shown that cells overexpressing 12/15-LO leads secretion of 
osteopontin and MCP-1 that cause IR (15). The existence of similar phenomenon cannot be 
denied with 8-LO.  Lipocalin 2 that is produced from adipocytes, is known to be an independent 
risk factors for inflammation, IR and diabetes (79). It has now been realized that any obesity 
inducing genes are also the culprits for induction of IR (80).  In   this study although the mice 
from three different genotypes were of comparable weights at the time of weaning (data shown 
as supplementary, tables 8 and 9 and figure15 ) there was significant difference in the weights of 
the mice at the time of experiment ( i.e. mice aged over 200 days) as mentioned previously.  So, 
we think that the IR seen in this study might be due to increase in obesity in KO mice as 
compared to the WT mice. However, we were unable to perform body composition analysis at 
the moment. 
            The other possibility for impaired insulin action in KO mice relative to WT might be due 
to defect in insulin receptor interaction. To elucidate the mechanism we performed glucose 
tolerance test again, but this time we halved the concentration of glucose administered i.e. 1mg 
per gram body weight of the mice. The age and weight distribution of the mice are shown as 
supplementary tables 10 and 11. There were no significant difference in weights and ages of the 
mice (one way ANOVA, p > 0.05). Comparison of AUC for glucose tolerance showed that WT 
mice were less glucose tolerant that the KO (figure 16) although this difference was not 
statistically significant (one –way ANOVA p= 0.315). This finding is just the opposite of what 
we found with administration of 2 mg/ gm BWt. of glucose (figure 10). One way of explaining 
this anomaly is by taking into account of insulin –receptor interaction constant Kd. We know that 
IR leads to hyperinsulinemia (47, 69, 70,75) here we assume the hyperinsulinemia is 
compensatory due to defect in insulin receptor interaction instead of other usual causes of IR. 
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Thus when 1mg per gram body weight of glucose is administered to the mice during IPGTT,  the 
hyperinsulinemia in the KO mice gets rid of the excess glucose effectively than the WT mice 
which may have relatively less insulin flowing in the blood stream. But this is not the case when 
glucose is injected at the rate of 2 mg per gram body weight of the mice. In this case since the 
receptor insulin interaction is better in WT mice as compared to the KO, the effectiveness of 
insulin is more pronounced in the former although both the mice might have optimum or 
equivalent amount of insulin produced ( figures 10, 12 and 16).  However, we could not measure 
insulin levels during the tests.  And there may also be a possibility that, signalling pathway 
downstream of insulin receptor interaction may have gone defective instead, which needs 
verification in future studies. 
            One important reason for the non-significant nature of the data presented in this study is 
due to the biased expression of Alox8 in mice tissues.  It is highly expressed in corneal 
epithelium however its mRNA has been detected in lung, colon, brain, footsole, forestomach or 
hair follicles (27).  Also, antitumorigenic role of Alox8 has been explored in relation to skin (9).   
Based on availability of data at present, we have no evidence that Alox8 is highly expressed in 
liver, skeletal muscle or adipose tissue, the hot spots for the glucose storage and insulin action. 
Furthermore, its orthologue 15 LO-2 has been known to be highly expressed in platelets rather 
than any other sites (www.genecards.org).  On these grounds, it is plausible to state that Alox8 
might play a biologically significant but statistically invalid role in lowering blood glucose level 
in mice.  
          Inaddition, PAS staining which is specific for glycogen showed a trend in the liver sections 
. Usually PAS staining can stain nonspecifically, hence to sort out specific binding with 
glycogen, PAS staining is followed by PASD after which only nonspecific stain will remain. 
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Hence, comparing the two staining slides we can figure out if glycogen was stored in the tissue.  
In our triplicate repeats of PAS (D) in three different genotypes of mice, the storage of glycogen 
was non-uniform (fig. 14). In case of row A, WT mice had highest glycogen storage intensity 
followed by KO and then Het. Whereas in case of rows B and C, there was an increase in 
intensity gradient while moving from WT to Het to KO with KO mice having the highest and 
WT mice with lowest PAS intensity. The reason for this discrepancy is obvious. WT liver 
responds to insulin better than the heterozygous or KO liver. This notion is also supported by the 
fact that liver from 80 % of diabetic patients often suffers from glycogen accumulation possibly 
due to long run of insulin insufficiency (71, 72).   Further, in our three batches of independent 
experiments (A, B and C) only B and C gave the repetitive pattern of glycogen accumulation in 
liver, this is due to the fact that the role of Alox8 in lowering blood glucose is biologically 
significant but not statistically. 
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   CHAPTER 5 
           CONCLUSION 
 
            Type II diabetes which comprises approximately 95% of all the diabetic cases is a costly 
disease. The most amenable way of combating the disease is by taking life style modification 
therapy where people with the illness is suggested for consuming a balanced diet and taking a 
regular exercise (67).  Besides there are currently available drugs that induces insulin sensitivity 
like Biguanides (Metformin) and TZDs (105) .  Taken together our data suggests that KO mice is 
less responsive to insulin than the WT mice implying that the findings when extrapolated to 
human subjects may require less insulin administration in 15 LO-2 diabetics as compared to 
those carrying its polymorphic alleles. However, such claim requires further validation. 
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       TABLES 
 
Table 1.  Distribution of ages and weights among the three genotypes. 
    Average     
Genotype No. Wt. (gms) Age (days) Std. Wt. Std. Age 
WT 6 30.67 288 2.16 25.56 
HET 5 34.7 296.6 2.01 24.39 
KO 5 33.46 287 1.91 43.41 
      
 
 
Table 2.  Blood glucose levels among the three genotypes during IPGTT. 
 
  Baseline 5 min 15min 30min 60min 120min 
 WT 117.67 238.17 372.17 266.5 158 97.83 
 WT-C 107 160.33 156.67 164.67 121.33 96 
Het 116.8 289.6 465.4 395 286.4 143.2 
Het-C 142 201.6 179.8 199.2 161.8 153 
KO 124.8 246.2 372.4 305.2 217.6 119.2 
KO-C 129.8 160.8 166 181.8 156 108.8 
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Table 3.   Mean AUC among the three genotypes during IPGTT. 
Genotype n AVG Std 
WT 6 8653.75 4548.8 
Het 5 20337 14737.4 
KO 5 12072.5 3218.69 
 
 
Table 4.   Distribution of ages and weights among the three genotypes. 
 
    Average     
Genotype No. Wt. (gms) Age (days) Std. Wt. Std. Age 
WT 6 33.48 301.17 2.81 24.79 
HET 5 37.18 310.2 2.36 24.72 
KO 5 35.84 301.8 1.49 44.22 
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Table 5.  Blood glucose levels among the three genotypes during IPITT. 
  Baseline(B) 5 min 15 min 30 min 60 min 120 min 
WT 108.33 116.5 111.67 110.33 116.5 150.5 
WT-C 135.33 192.67 200 203.67 168.83 138.83 
Het 172.8 176.8 178.4 135.2 170 166.8 
Het-C 182.6 223.2 249.8 254.6 206 171 
KO 156.4 193.6 164 175.4 221.2 186 
KO-C 156 230 275.8 246.8 176.8 167.6 
 
 
 
Table 6.   Mean drop in blood glucose level among the three genotypes five minutes after insulin 
administration via intraperitoneal route. C- control, T- test. 
 
 
∆ 5min (C-T) AVG SE 
WT 76.17 25.09 
Het 46.4 43.49 
KO 36.4 36.98 
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      FIGURES 
 
 
 
  Fig. 7 Mode of insulin action in liver cell.   
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Fig. 8  Genotyping 
 
 
Fig. 9  Dynamics of blood glucose level with time among three genotypes during IPGTT. Error 
bars denote  ± SEM  and  n =  6, 5, 5 for WT, Het & KO resp. . C stands for control of the 
respective genotypes. 
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Fig. 10 AUC analysis of data obtained from IPGTT. Error bars denote ± SEM and  n =  6, 5, 5 
for WT, Het & KO resp. . 
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Fig. 11 Dynamics of blood glucose level with time among three genotypes during IPITT. Error 
bars denote  ± SEM  and  n =  6, 5, 5 for WT, Het & KO resp. . C stands for control of the 
respective genotypes. 
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Fig. 12  Drop in blood glucose level five minutes interval after insulin administration  among 
three genotypes during IPITT. Error bars denote  ± SEM  and  n =  6, 5, 5 for WT, Het & KO 
resp. . 
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Fig. 13 Representative H & E staining of liver sections from three different genotypes. 
                 
Fig. 14 PAS (upper row) and PAS-digestion (lower row) staining of liver sections from three 
different genotypes. (A, B & C denotes three different batches of experiments and + denotes 
degree of PAS intensity ). Magnification 4X. 
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Fig. 16 AUC analysis of data obtained from IPGTT ( 1mg/gm BWt.) . Error bars denote ± SEM 
and  n =  6, 5, 5 for WT, Het & KO resp. . 
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     APPENDIX-A 
         SUPPLEMENTARY 
GTT 
 
 
 
 
 
 
WT 
 
Age(days) Sex 
Weight(gms
) 
Baseline(B
) 5 min 15 min 30 min 60 min 120 min 
 
266 Male 31 111 244 296 226 183 98 
 
266 Male 31 84 264 331 250 169 79 
 
266 Male 27 162 217 279 233 146 88 
 
321 Male 30 151 242 331 334 191 126 
 
314 Male 33.6 82 265 577 278 111 101 
 
295 Male 31.4 116 197 419 278 148 95 
AVG 288 #DIV/0! 30.67 117.67 238.17 372.17 266.5 158 97.83 
Std 25.56 #DIV/0! 2.16 
      n 6 
 
SEM 13.58 10.92 45.47 16.18 11.96 6.49 
Control WT 
 
Age(days) Sex Weight(gms) Baseline(B) 5 min 15 min 30 min 60 min 120 min 
 
266 Male 31 89 193 139 174 95 96 
 
266 Male 31 112 106 136 134 112 101 
 
266 Male 27 103 175 156 136 94 82 
 
321 Male 30 120 166 159 240 228 105 
 
314 Male 33.6 81 144 120 147 99 101 
 
295 Male 31.4 137 178 230 157 100 91 
AVG 
   
107 160.33 156.67 164.67 121.33 96 
Std 
         n 6 
 
SEM 8.39 12.71 15.78 16.22 21.49 3.43 
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Het  
 
Age(days) Sex Weight(gms) Baseline(B) 5 min 15 min 30 min 60 min 120 min 
 
322 Male 36.4 108 342 479 323 172 129 
 
266 Male 37.2 102 219 285 291 161 124 
 
314 Male 34 97 264 444 346 374 113 
 
276 Male 33.4 94 393 600 600 526 257 
 
305 Male 32.5 183 230 519 415 199 93 
AVG 296.6 #DIV/0! 34.7 116.8 289.6 465.4 395 286.4 143.2 
Std 24.39 #DIV/0! 2.01 
      n 5 
        
   
SEM 16.72 33.64 52.05 55.15 71.25 29.11 
Control Het  
 
Age(days) Sex Weight(gms) Baseline(B) 5 min 15 min 30 min 60 min 120 min 
 
322 Male 36.4 120 154 206 138 137 107 
 
266 Male 37.2 96 133 169 142 142 94 
 
314 Male 34 136 191 139 249 168 138 
 
276 Male 33.4 122 240 197 151 171 290 
 
305 Male 32.5 236 290 188 316 191 136 
AVG 
   
142 201.6 179.8 199.2 161.8 153 
Std 
         n 5 
 
SEM 24.36 28.61 11.90 35.68 9.96 35.27 
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KO 
 
Age(days) Sex Weight(gms) Baseline(B) 5 min 15 min 30 min 60 min 120 min 
 
322 Male 36 87 318 335 200 130 101 
 
322 Male 34.6 103 251 474 352 134 104 
 
221 Male 32 131 309 298 283 366 108 
 
266 Male 33.4 97 180 255 296 199 132 
 
304 Male 31.3 206 173 500 395 259 151 
AVG 287 #DIV/0! 33.46 124.8 246.2 372.4 305.2 217.6 119.2 
Std 43.41 #DIV/0! 1.91 
      n 5 
        
   
SEM 21.57 30.71 48.64 33.09 44.01 9.65 
Control KO 
 
Age(days) Sex Weight(gms) Baseline(B) 5 min 15 min 30 min 60 min 120 min 
 
322 Male 36 81 118 108 103 133 96 
 
322 Male 34.6 127 175 178 152 220 123 
 
221 Male 32 100 195 160 344 178 87 
 
266 Male 33.4 150 173 166 144 160 120 
 
304 Male 31.3 191 143 218 166 89 118 
AVG 
   
129.8 160.8 166 181.8 156 108.8 
Std 
         n 5 
 
SEM 19.28 13.54 17.67 41.88 21.92 7.25 
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Glucose (mg/dL) Area under the curve 
 WT 0 min 5 min 15 min 30 min 60 min 120 min Total Baseline Above Baseline 
#1 111 244 296 226 183 98 22067.5 13320 8747.5 
#2 84 264 331 250 169 79 21927.5 10080 11847.5 
#3 162 217 279 233 146 88 19972.5 19440 532.5 
#4 151 242 331 334 191 126 26220 18120 8100 
#5 82 265 577 278 111 101 23685 9840 13845 
#6 116 197 419 278 148 95 22770 13920 8850 
        
AVG 8653.75 
        
Std. 4548.80 
        
SEM 1857.04 
 
Glucose (mg/dL) Area under the curve 
 Het 0 min 5 min 15 min 30 min 60 min 120 min Total Baseline Above Baseline 
#1 108 342 479 323 172 129 27700 12960 14740 
#2 102 219 285 291 161 124 22972.5 12240 10732.5 
#3 97 264 444 346 374 113 35777.5 11640 24137.5 
#4 94 393 600 600 526 257 55562.5 11280 44282.5 
#5 183 230 519 415 199 93 29752.5 21960 7792.5 
        
AVG 20337 
        
Std. 14737.44 
        
SEM 6590.78 
 
Glucose (mg/dL) Area under the curve 
KO 0 min 5 min 15 min 30 min 60 min 120 min Total Baseline Above Baseline 
#1 87 318 335 200 130 101 20170 10440 9730 
#2 103 251 474 352 134 104 25135 12360 12775 
#3 131 309 298 283 366 108 32447.5 15720 16727.5 
#4 97 180 255 296 199 132 24355 11640 12715 
#5 206 173 500 395 259 151 33135 24720 8415 
        
AVG 12072.5 
        
Std. 3218.69 
        
SEM 1439.44 
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                    ITT 
 
 
 
 
 
 
 
 
WT 
 
Age(days) Sex Weight(gms) Baseline(B) 5 min 15 min 30 min 60 min 120 min 
 
280 Male 34.5 106 115 138 132 97 143 
 
280 Male 29.7 113 129 105 126 155 191 
 
280 Male 35.8 128 124 87 95 156 165 
 
334 Male 32.5 103 137 105 133 124 137 
 
326 Male 31.3 90 89 74 72 71 106 
 
307 Male 37.1 110 105 161 104 96 161 
AVG 301.17 
 
33.48 108.33 116.50 111.67 110.33 116.50 150.50 
SEM 10.12 
 
1.15 5.10 7.13 13.22 9.96 14.11 11.80 
Control WT 
 
Age(days) Sex Weight(gms) Baseline(B) 5 min 15 min 30 min 60 min 120 min 
 
280 Male 34.5 112 151 196 124 133 107 
 
280 Male 29.7 216 212 255 266 224 167 
 
280 Male 35.8 157 316 174 162 194 116 
 
334 Male 32.5 115 154 249 323 155 161 
 
326 Male 31.3 93 158 155 199 172 128 
 
307 Male 37.1 119 165 171 148 135 154 
AVG 
   
135.33 192.67 200.00 203.67 168.83 138.83 
   
SEM 18.25 26.32 17.31 31.27 14.50 10.27 
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   Het  
 
Age(days) Sex Weight(gms) Baseline(B) 5 min 15 min 30 min 60 min 120 min 
 
280 Male 38.8 120 236 213 186 172 157 
 
326 Male 38.6 135 116 135 152 124 122 
 
289 Male 33.2 127 164 164 119 92 173 
 
318 Male 36.8 331 202 267 114 342 241 
 
338 Male 38.5 151 166 113 105 120 141 
AVG 310.2 
 
37.18 172.8 176.8 178.4 135.2 170 166.8 
SEM 11.06 
 
1.06 39.89 20.15 27.76 14.98 44.88 20.39 
Control Het  
 
Age(days) Sex Weight(gms) Baseline(B) 5 min 15 min 30 min 60 min 120 min 
 
280 Male 38.8 144 214 292 267 265 141 
 
326 Male 38.6 226 178 174 277 220 196 
 
289 Male 33.2 150 374 307 329 189 133 
 
318 Male 36.8 195 192 285 239 192 257 
 
338 Male 38.5 198 158 191 161 164 128 
AVG 
   
182.6 223.2 249.8 254.6 206 171 
   
SEM 15.54 38.79 27.83 27.56 17.21 24.71 
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KO 
 
Age(days) Sex Weight(gms) Baseline(B) 5 min 15 min 30 min 60 min 120 min 
 
235 Male 37 126 162 170 164 315 391 
 
280 Male 36.4 155 202 110 243 215 125 
 
338 Male 35.8 211 145 179 176 168 156 
 
338 Male 36.7 161 309 199 149 266 132 
 
318 Male 33.3 129 150 162 145 142 126 
AVG 301.8 
 
35.84 156.4 193.6 164 175.4 221.2 186 
SEM 19.77 
 
0.67 15.30 30.54 14.84 17.78 31.58 51.56 
Control KO 
 
Age(days) Sex Weight(gms) Baseline(B) 
5 
min 
15 
min 
30 
min 
60 
min 
120 
min 
 
235 Male 37 128 215 341 292 176 174 
 
280 Male 36.4 196 183 210 306 174 164 
 
338 Male 35.8 162 244 229 238 246 250 
 
338 Male 36.7 178 234 250 177 153 126 
 
318 Male 33.3 116 274 349 221 135 124 
AVG 
   
156 230 275.8 246.8 176.8 167.6 
   
SEM 15.01 15.14 28.98 23.62 18.86 22.89 
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WT 
Age(days) Sex Weight(gms) 5 min(C) 5 min(T) C-T 
280 Male 34.5 151 115 36 
280 Male 29.7 212 129 83 
280 Male 35.8 316 124 192 
334 Male 32.5 154 137 17 
326 Male 31.3 158 89 69 
307 Male 37.1 165 105 60 
    
AVG 76.17 
    
SE 25.09 
 
 
 
 
 
 
 
 
 
 
 
Het 
Age(days) Sex Weight(gms) 5 min(C) 5 min(T) C-T 
280 Male 38.8 214 236 -22 
326 Male 38.6 178 116 62 
289 Male 33.2 374 164 210 
318 Male 36.8 192 202 -10 
338 Male 38.5 158 166 -8 
    
AVG 46.40 
    
SE 43.49 
 
 
 
     
 
 
WT 
Age(days) Sex Weight(gms) 
15 
min(C) 
15 
min(T) 
C-T 
280 Male 34.5 196 138 58 
280 Male 29.7 255 105 150 
280 Male 35.8 174 87 87 
334 Male 32.5 249 105 144 
326 Male 31.3 155 74 81 
307 Male 37.1 171 161 10 
    
AVG 88.33 
    
SE 21.61 
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Het 
Age(days) Sex Weight(gms) 15 min(C) 15 min(T) C-T 
280 Male 38.8 292 213 79 
326 Male 38.6 174 135 39 
289 Male 33.2 307 164 143 
318 Male 36.8 285 267 18 
338 Male 38.5 191 113 78 
    
AVG 71.40 
    
SE 21.36 
KO 
Age(days) Sex Weight(gms) 5 min(C) 5 min(T) C-T 
235 Male 37 215 162 53 
280 Male 36.4 183 202 -19 
338 Male 35.8 244 145 99 
338 Male 36.7 234 309 -75 
318 Male 33.3 274 150 124 
    
AVG 36.40 
    
SE 36.98 
KO 
Age(days) Sex Weight(gms) 15 min(C) 15 min(T) C-T 
235 Male 37 341 170 171 
280 Male 36.4 210 110 100 
338 Male 35.8 229 179 50 
338 Male 36.7 250 199 51 
318 Male 33.3 349 162 187 
    
AVG 111.80 
    
SE 29.00 
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Table 7. Comparison of baseline blood glucose levels between two genotypes after 5 hours of 
fasting during IPITT. 
WT KO 
106 126 
113 155 
128 211 
103 161 
90 129 
110   
  
Table 8.   Mean  weaning ( 21 days) weight distribution between two sexes among the three 
genotypes of Alox8 mice. 
AVG Genotype SE Std 
Wts.(gm) WT Het KO WT Het KO WT Het KO 
M 11.11 11.32 11.49 0.63 0.66 1.09 2.37 2.28 3.08 
F 11.58 11.16 10.58 0.62 0.6 0.66 2.25 2 1.98 
 
 
Table 9. Distribution of sexes among the three genotypes of Alox8 mice at the time of weaning. 
  Genotypes 
Sexes  WT Het KO 
Male 14 12 8 
Female 13 11 9 
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Table 10. Age and weight distribution among the three genotypes during IPGTT (1mg/ gm 
BWt.).  
  Average       
Genotype Wt. (gms) Age(days) No. Std Wt. Std Age 
WT 33.05 356.83 6 2.74 24.33 
HET 35.86 363.4 5 4.09 22.97 
KO 35.56 356.8 5 3.55 43.31 
 
One way- ANOVA of ages in three groups , p = 0.926 
One way- ANOVA of Wts in three groups , p =  0.355 
 
 
 
Table 11.  Dynamics of blood glucose level with time  during IPGTT ( 1mg/ gm BWt. ) 
  Baseline 5 min 15min 30min 60min 120min 
 WT 138.17 252 285.67 200.33 182.67 127.5 
Het 166.4 280.8 368.4 224.2 187.2 135.6 
KO 211.2 294.6 289.2 284.2 211 136.8 
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One way ANOVA for weights of males p= 0.941 
One way ANOVA for weights of females p= 0.553 
students' t-test for  weights in WT between sexes , p= 0.6124 
students' t-test for  weights in Het between sexes , p= 0.8663 
students' t-test for  weights in KO between sexes , p= 0.4747 
 
Fig. 15  Comparison of weights distribution between sexes among three genotypes of Alox8 
mice at the time of weaning. Error bar denotes ±SEM. For n values see table 8 above. 
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Fig. 17 Dynamics of blood glucose level during IPGTT ( 1mg/ gram BWt.). 
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                      IPGTT (1mg/gm BWt) 
 
 
 
 
Glucose (mg/dL) Area under the curve 
KO 0 min 5 min 15 min 30 min 60 min 120 min Total Baseline 
Above 
Baseline 
#1 244 283 244 297 149 119 22740 29280 -6540 
#2 132 290 202 306 158 119 22595 15840 6755 
#3 174 333 321 244 237 170 28200 20880 7320 
#4 176 274 256 239 186 111 22772.5 21120 1652.5 
#5 330 293 423 335 325 165 35422.5 39600 -4177.5 
        
AVG 1002 
        
Std. 6267.90 
        
SEM 2803.09 
 
 
 
Glucose (mg/dl) Area under the curve 
 WT 0 min 5 min 15 min 30 min 60 min 120 min Total Baseline 
Above 
Baseline 
#1 128 246 447 241 235 179 29120 15360 13760 
#2 97 228 196 132 110 92 15082.5 11640 3442.5 
#3 137 251 290 211 225 158 25462.5 16440 9022.5 
#4 168 306 282 222 165 112 22020 20160 1860 
#5 136 215 234 197 206 120 22180 16320 5860 
#6 163 266 265 199 155 104 20287.5 19560 727.5 
        
AVG 5778.75 
        
Std. 4910.37 
        
SEM 2004.65 
 
Glucose (mg/dL) Area under the curve 
 Het 0 min 5 min 15 min 30 min 60 min 120 min Total Baseline 
Above 
Baseline 
#1 142 193 263 194 177 131 21350 17040 4310 
#2 230 263 572 258 183 148 28177.5 27600 577.5 
#3 182 311 306 202 183 123 23082.5 21840 1242.5 
#4 158 359 470 272 224 116 28642.5 18960 9682.5 
#5 120 278 231 195 169 160 22065 14400 7665 
        
AVG 4695.5 
        
Std. 3959.73 
        
SEM 1770.85 
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